Fairvalue-Calculator Fairvalue-Calculator
EN DE

Observe Medical ASA (OBSRV) Fair Value & Analysis

Healthcare · NO · Market cap 137M NOK

Pricekr 1.08
Fair Valuekr 0.9900
Upside-8.3%
Quality95/100
Evidence: Low Range kr 0.7400 – kr 1.24

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Observe Medical ASA (OBSRV) currently trades at kr 1.08, while our model-based Fair Value estimate is kr 0.9900 — implying the stock looks roughly 8.3% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Observe Medical ASA develops and commercialize medical technology products for patients, healthcare professionals, and hospitals in Europe, Asia, and the Americas. The company offers UnoMeter portfolio comprising Unometer, Safeti Plus, Unometer 500, and UnoMeter AbdoPressure products used for manual urine output measurement and for measuring intra-abdominal pressure. It also provides Sippi, a digital and automated urine measurement system for urine monitoring and biofilm control. Observe Medical ASA was founded in 2009 and is headquartered in Oslo, Norway.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is Observe Medical ASA (OBSRV) undervalued?
As of Jun 24, 2026, our model estimates a fair value of kr 0.9900 versus a price of kr 1.08 — about −8% (overvalued). Model-based estimate, not financial advice.
What is the fair value of OBSRV?
Our 21-model fair value for Observe Medical ASA is kr 0.9900 (as of Jun 24, 2026), built from audited fundamentals. The current price is kr 1.08.
What is the quality score of OBSRV?
Observe Medical ASA has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.